ALS, MND, or PLS registry study
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This observational study creates a registry for people with ALS, MND, or PLS. It helps researchers better understand these conditions and find possible treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALS (Lou Gehrig's disease), MND (motor neuron disease), or PLS (primary lateral sclerosis)
- You do not smoke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.
This study collects information in a registry about assistive devices, medicines, and healthcare support for people with long-term neurological conditions like ALS and SMA. It may help researchers understand what treatments and supports are used and how they relate to patients’ needs over time.
This study collects and stores medical information from people diagnosed with ALS or certain related conditions affecting movement. It may help researchers better understand how these illnesses change over time and improve future treatments.
This study follows people living with amyotrophic lateral sclerosis (ALS) over time. It may help researchers better understand ALS and track changes that could guide future treatments.
This study looks at people with amyotrophic lateral sclerosis (ALS), people who might have ALS, and also people related to someone with ALS. It may help researchers better understand ALS and related “motor neuron” conditions, and it involves participation that may include blood tests.
This study will create a registry of people with ALS in Thailand. The goal is to track the disease and to improve the care and treatment for future patients.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.